

Quality Initiative In Pathology

'Harmonisation of Laboratory Testing'



Harmonisation: what do we mean?

Agreement of test results irrespective of the method used or the testing laboratory

Requires:

- Common terminology and units of reporting
- Common reference intervals and clinical decision limits.

Key drivers of harmonisation in pathology

Safety Issues

Medical referrers/ GPs not aware of methodological or unit reporting differences

IT Issues and eHMR

e-Health providers unaware of complex methodological problems in pathology testing

Potential for wrong result interpretation in both situations.

pathologyharmonise standards in UK pathology

Pathology Harmony - a method

In 2007, during Review data of the Birmingham No underlying Consider reasons meetings a 'X'. Apply science explains for variation of methodological scientific 'X' variation approach to knowledge to harmonisation gradually reach consensus evolved. This is best shown by Justified reason the following diagram. for variation of 'X' Drop 'X' and move on Harmonise 'X'

Berg J, Lane V. Ann Clin Biochem 2011

AACC Harmonization Initiative

Harmonization.net

| | | | | | | | | | | |

- A global infrastructure and systematic approach for harmonization (and standardization) for all measurands is needed.
- ➤ The goal for the Steering Committee and Task Forces is to have an operational harmonization process in place by the end of 2012.
- Implementation of a comprehensive harmonization process will require the involvement and cooperation of all interested stakeholders.





Key Harmonisation Activities in Australia

- Standardisation of Pathology Units and Terminology (PUTS)
- Harmonised Reference Intervals and Decision Limits
- 3. Critical Results choice of key analytes and common communication processes
- 4. Best practice methodology for selection and adoption of laboratory guidelines for local use in Australia.

Methodology

Activities include:

- Collation and dissemination of the evidence supporting the above
- Setting up of working groups to collate the evidence
- A Workshop to discuss the results with all Australian laboratories and aimed at reaching a consensus on common Reference Intervals
- Support tools for laboratories to assist in implementation of harmonisation.

Application of Stockholm Heirarchy to defining quality of RIs and clinical decision limits

Level	Principle	Reference Limits	Common Interval
1	Clinical Outcome	Based on clinical outcome	Glucose, Lipids
2A	Biological variation	2.5%-97.5% distribution of reference population	NORIP (Direct) SONIC (Indirect)
2B	Clinician Survey	Based on survey of clinician response to results.	Troponin
3	Professional Recommendations	Based on Laboratory Experts.	ARQAG SIQAG
4	Proficiency survey	Based on survey of common reference intervals used.	UK Harmony
5	State of the Art	Based on what is available.	Kit Insert


Sikaris K. Clin Biochem Rev 2012;33 (November)

Checklist for setting an RI

- 1. Define analyte (measurand)
- 2. Define assays used, accuracy base, analytical specificity
- 3. Consider important pre-analytical differences, actions in response to interference
- 4. Define distribution of RI values (e.g. central 95%)
- 5. Describe evidence for merging of RIs
 - data sources (literature, lab surveys, manufacturer)
 - data mining
 - bias goal as quality criterion for acceptance
- 6. Consider partitioning based on age, sex, etc
- 7. Define degree of rounding
- 8. Clinical considerations of the RI
- 9. Consider use of common RI
- 10. Document and implement.

Potassium

- Population RI
- mmol/L
- Assays both direct and indirect
- No expected methodological differences; analytically there are no differences
- Serum vs Plasma:
 - serum approx. 0.3 mmol/L higher
 - serum preferred sample for RI
- Pre-analytical: haemolysis indices to be harmonised
- Gender and age differences
 - URL all 5.0 mmol/L up to 80 y
 - URL up to 5.2 mmol/L for 80 y+
- Clinical consideration: RI based on healthy individuals not hospital patients
- Significant figures to 1 decimal place
- Proposed RI (regardless of preanalytical conditions):
 SERUM 3.5 – 5.2 mmol/L



Green

Bias would not prevent common reference intervals a. All results fall within the RCPA QAP ALP for the analyte.

b. Regression line does not cross the RCPA QAP ALP within the current manufacturer quoted reference intervals.

Proposed Adult Reference Intervals

Analyte	Male	Female
Calcium	2.15 – 2.55 mmol/L	
Adjusted Calcium	2.15 – 2.55 mmol/L	
Phosphate	0.75 – 1.50 mmol/L	
Magnesium 0.70 – 1.10		0 mmol/L
LD [L to P]	120 – 250 U/L	
Sodium	135 – 145 mmol/L	
Potassium	3.5 – 5.2 mmol/L (serum)	
Chloride	95 – 110 mmol/L	
Bicarbonate	22 – 32 mmol/L	
Creatinine	60 – 110 μmol/L	45 – 90 μmol/L
ALP	30 – 110 U/L	
AST	<40 U/L	<35 U/L
ALT	<40 U/L	<30 U/L
Total Protein	60 – 80 g/L	





Critical Laboratory Result Management

- A preliminary survey was conducted by AACB Critical Laboratory Results WG & RCPA QAP
- Part of this initiative is to establish a degree of concordance between critical tests, critical limits and reporting practices used by laboratories for common biochemistry analytes
- A systematic review of the literature was undertaken & a survey is pending in Europe
- Best practice recommendations are required to provide high quality and safe service to patients.

HARMONISATION of LABORATORY TESTING – a global activity

Pre-analytical

Patient safety

Harmonised Reporting Units ጼ Test **Terminology**

Patient safety

Method **Harmonisation** (e.g. immunoassay analytes)

& same cut-offs

Patient safety

Harmonised RIs

Decision Limits

Consistent patient

interpretation

Critical Tests. Critical Limits

their Communication

Patient Safety

Education of Consumer **GP Specialist**

Patient buy-in of pathology

Pre-analytical

Right test Right time Right patient

Harmonised **Reporting Units**

Troponin in ng/L No decimals Whole numbers

Patient safety

Method **Harmonisation**

PSA & same cut-offs

Patient safety

Harmonised RIs

Na, K

Decision Limits

ACR

Consistent patient

interpretation

Critical Limits

Calcium (mmol/L) Low 1.75

High 3.00

Patient Safety

Education of

Consumer **Advocate** groups

Patient buy-in of pathology